Lundbeck Plans To Rebuild R&D Pipeline Mean Likely Job Losses
130-160 Positions Could Go In R&D
Lundbeck wants to rebuild its R&D pipeline of products to treat brain disorders after recent disappointments, a process that could lead to job losses among the research organization, and more emphasis on deal-making.
You may also be interested in...
The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Laura Soucek, one of In Vivo’s 2020 Rising Leaders, is hoping to take Barcelona-based start-up Peptomyc to the next level. The company is nearing the clinic with an inhibitor of the transcription factor Myc, which is involved in the regulation of cellular proliferation, but can also be a driver of cancer.